The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of KRAS exon 3, exon 4, and NRAS mutations in pathological stage III colon cancer.
 
Kaoru Yoshikawa
No Relationships to Disclose
 
Hiroki Osumi
Honoraria - Bristol-Myers Squibb Japan; Guardant Health; Lilly; Merck; Merck Serono; Taiho Pharmaceutical
 
Akira Ooki
Honoraria - Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo; Ono Pharmaceutical
 
Shota Fukuoka
No Relationships to Disclose
 
Eiichiro Toyokawa
No Relationships to Disclose
 
Koichiro Yoshino
No Relationships to Disclose
 
Shohei Udagawa
No Relationships to Disclose
 
Tatsuki Noguchi
No Relationships to Disclose
 
Takashi Sakamoto
No Relationships to Disclose
 
Shimpei Matsui
No Relationships to Disclose
 
Toshiki Mukai
No Relationships to Disclose
 
Tomohiro Yamaguchi
No Relationships to Disclose
 
Keitaro Shimozaki
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Mariko Ogura
No Relationships to Disclose
 
Keisho Chin
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takashi Akiyoshi
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha